An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.

APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial

HomePublicationsAPOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial

Publication Information

DOI

10.1016/j.ekir.2017.03.008

PubMed ID

28758155

Public Release Type

Journal

Publication Year

2017

Authors

Freedman Barry I., Rocco Michael V., Bates Jeffrey T., Chonchol Michel, Hawfield Amret T., Lash James P., Papademetriou Vasilios, Sedor John R., Servilla Karen, Kimmel Paul L., Wall Barry M., Pajewski Nicholas M.

Studies

AASK Trial

Abstract

Relationships between apolipoprotein L1 gene (APOL1) renal-risk variants (RRVs) and cardiovascular disease (CVD) remain controversial. To clarify associations between APOL1 and CVD, a total of 2568 African American Systolic Blood Pressure Intervention Trial (SPRINT) participants were assessed for the incidence of CVD events (primary composite including nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and CVD death), renal outcomes, and all-cause mortality.